Physician profile
Rasmoni Roy
NPI 1215378948
$13,356.06
in general payments reported to CMS, 2019-2025
58 companies · $4,006 in 2025
The $4,006 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $57.01 · 2021: $96.90 · 2022: $2,472 · 2023: $2,531 · 2024: $3,761 · 2025: $4,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,297.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,399.02 | 2019-2025 | Botox, Duopa, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,215.34 | 2019-2025 | |
| Pfizer INC. | $820.95 | 2023-2025 | |
| Ucb, INC. | $707.70 | 2019-2025 | Rystiggo, Nayzilam, Zilbrysq |
| Argenx US, INC. | $702.73 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $545.15 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Genentech USA, INC. | $441.32 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Celgene Corporation | $439.22 | 2022-2025 | Zeposia |
| Amgen INC. | $415.62 | 2019-2025 | Uplizna, Aimovig |
| Eisai INC. | $406.34 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $359.78 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Alexion Pharmaceuticals, INC. | $356.54 | 2019-2024 | Ultomiris |
| Neurocrine Biosciences, INC. | $355.08 | 2022-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $339.15 | 2022-2025 | Vyepti, Rexulti |
| Horizon Therapeutics Plc | $319.41 | 2022-2023 | Uplizna |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasmoni Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.